Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Clinical Nephrology
You have accessRestricted Access

Left Ventricular Morphology and Function in Patients with Atherosclerotic Renovascular Disease

Julian R. Wright, Ala’a E. Shurrab, Anne Cooper, Paul R. Kalra, Robert N. Foley and Philip A. Kalra
JASN September 2005, 16 (9) 2746-2753; DOI: https://doi.org/10.1681/ASN.2005010043
Julian R. Wright
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ala’a E. Shurrab
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Cooper
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul R. Kalra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert N. Foley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip A. Kalra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Article Figures & Data

Tables

    • View popup
    Table 1.

    Demographic, BP, and echocardiographic data for ARVD and control groupsa

    ARVDPbAOR (95% CI)c of ARVDPd
    No (n = 50)Yes (n = 79)
    Age (yr)69 ± 971 ± 7NS1.04 (0.98 to 1.10)0.2
    Gender0.9
        male38.0%58.2%NS1
        female62.0%41.8%0.93 (0.37 to 2.32)
    Diabetes30.0%24.1%NS0.81 (0.30 to 2.18)0.7
    Ischemic heart disease22.0%32.9%NS1.56 (0.55 to 4.42)0.4
    eGFR (ml/min)33 ± 1636 ± 19NS1.01 (0.98 to 1.03)0.8
    24-h urinary protein (g/d)1.4 ± 2.00.4 ± 0.5<0.0010.21 (0.07 to 0.62)0.005
    24-h systolic BP (mmHg)138 ± 17140 ± 19NS1.02 (1.00 to 1.05)0.07
    24-h diastolic BP (mmHg)75 ± 1273 ± 13NS1.00 (0.96 to 1.04)0.9
    Hemoglobin (g/L)124 ± 18127 ± 20NS0.99 (0.97 to 1.02)0.6
    LV hypertrophy46.0%78.5%<0.0015.54 (2.04 to 15.02)0.001
    LVMI (g/m2)116 ± 33183 ± 74<0.0011.04 (1.02 to 1.05)f<0.001
    LVEF (%)57 ± 1253 ± 12NS0.97 (0.94 to 1.01)0.16
    LVEDV index (ml/m2)34 ± 1682 ± 35<0.0011.18 (1.09 to 1.28)<0.001
    Two or more LV diastolic function abnormalitiese12.0%40.5%<0.00116.3 (3.9 to 68.5)0.001
    • ↵a AOR, adjusted odds ratio; ARVD, atherosclerotic renovascular disease; CI, confidence interval; eGFR, estimated GFR; LV, left ventricular; LVH, LV hypertrophy; LVMI, LV mass index; LVEF, LV ejection fraction; LVEDV, LV end-diastolic volume.

    • ↵b Compared using the χ2 test for categorical variable and ANOVA test for continuous variables.

    • ↵c Using multiple logistic regression, with the presence (coded 1) or absence (coded 0) of ARVD as the dependent variable and adjusted for age, gender, diabetes, ischemic heart disease, eGFR, 24-h urinary protein, 24-h systolic BP, and hemoglobin.

    • ↵d Adjusted for age, gender, diabetes, ischemic heart disease, eGFR, 24-h urinary protein, and hemoglobin.

    • ↵e Categories were combined because no patient in the control group had three diastolic function abnormalities.

    • ↵f Each 1-g/m2 increment in LVMI is associated with a 4% increment in the AOR of ARVD.

    • View popup
    Table 2.

    Demographic, BP, and echocardiographic data for ARVD patients stratified according to renal functiona

    Patients with ARVD (n = 79)Preserved Renal FunctionModerate Renal FailureSevere Renal FailureP
    n16 (20.3%)35 (44.3%)28 (35.4%)
    Age (yr)64.1 ± 7.572.5 ± 5.672.3 ± 7.7<0.005
    eGFR (μmol/L)68 ± 1236 ± 719 ± 4<0.001
    Proteinuria (g/L)0.1 ± 0.20.3 ± 0.40.6 ± 0.6<0.005
    Overall systolic BP (mmHg)134.6 ± 19.1140.1 ± 16.1141.4 ± 22.4NS
    Overall diastolic BP (mmHg)71.6 ± 8.973.1 ± 13.772.7 ± 14.0NS
    Overall MAP (mmHg)93.9 ± 9.996.9 ± 13.197.1 ± 16.1NS
    LVH (%)68.882.878.6NS
    LVMI (g/m2)148.9 ± 45.5184.9 ± 69.8188.3 ± 82.5NS
    LVEF (%)55.7 ± 14.054.9 ± 9.948.6 ± 11.9NS
    LVEDD (cm)5.2 ± 0.65.4 ± 0.95.4 ± 1.2NS
    LVEDV (ml)144.0 ± 44.3134.5 ± 35.7166.7 ± 87.7NS
    Cholesterol (mmol/L)4.7 ± 1.24.7 ± 0.94.7 ± 1.4NS
    Calcium-phosphate product (mmol/L)2.4 ± 0.62.5 ± 0.53.2 ± 0.8<0.001
    • ↵a MAP, mean arterial BP; LVEDD, LV end-diastolic diameter.

    • View popup
    Table 3.

    LVMI and prevalence of LVH in ARVD patients compared with control patients and stratified according to renal functional grouping

    Control Group (n = 50)ARVD Group (n = 79)P
    LVMI (g/m2)
        preserved renal function101.1 ± 24.9148.9 ± 45.5<0.05
        moderate renal failure110.8 ± 37.5184.9 ± 69.8<0.001
        severe renal failure126.7 ± 28.0188.3 ± 82.5<0.005
        P(between renal function categories)0.1390.171
    Prevalence of LVH (%)
        preserved renal function33.368.8NS
        moderate renal failure43.582.8<0.05
        severe renal failure52.478.6NS
        P(between renal function categories)0.6730.173
    Cholesterol (mmol/L)4.4 ± 1.04.7 ± 1.1NS
    Calcium-phosphate product (mmol/L)3.0 ± 1.02.7 ± 0.7NS
    • View popup
    Table 4.

    Demographic, BP, and echocardiographic data for residual renal artery patency groups and for unilateral and bilateral renal artery disease groups

    Baseline (n = 79)Mild ARVDModerate ARVDSevereARVDPUnilateral ARVDBilateral ARVDP
    n26 (32.9%)45 (57%)8 (10.1%)51 (64.6%)28 (35.4%)
    Age (yr)71.3 ± 5.070.4 ± 8.670.3 ± 8.6NS70.1 ± 8.171.9 ± 6.3NS
    eGFR (ml/min)36.4 ± 20.635.9 ± 18.437.7 ± 20.9NS37.9 ± 19.233.3 ± 19.1NS
    Proteinuria (g/24 h)0.4 ± 0.41.5 ± 0.30.5 ± 0.9NS0.3 ± 0.40.4 ± 0.6NS
    24-h systolic BP (mmHg)141.0 ± 21.6138.5 ± 19.1139.6 ± 9.9NS141.5 ± 18.6135.7 ± 19.6NS
    24-h diastolic BP (mmHg)72.4 ± 14.172.1 ± 12.476.4 ± 12.0NS74.8 ± 13.168.9 ± 11.7NS
    24-h MAP (mmHg)96.8 ± 15.295.6 ± 13.599.1 ± 9.1NS98.8 ± 13.792.1 ± 12.6<0.05
    LVH (%)76.980.075.0NS74.585.7NS
    LVMI (g/m2)174.1 ± 49.7181.5 ± 83.2179.0 ± 67.3NS167.1 ± 58.8200.2 ± 87.4<0.05
    LVEF (%)49.2 ± 13.455.3 ± 9.950.93 ± 14.4NS53.5 ± 11.851.5 ± 11.8NS
    LVEDD (cm)5.3 ± 0.65.4 ± 1.15.4 ± 0.8NS5.2 ± 0.85.8 ± 1.1<0.01
    LVEDV (ml)150.9 ± 61.9147.6 ± 65.9139.0 ± 36.1NS141.4 ± 50.1159.6 ± 78.3NS
    Cholesterol (mmol/L)4.5 ± 1.04.8 ± 1.15.0 ± 1.5NS4.7 ± 1.14.7 ± 1.2NS
    Calcium-phosphate product (mmol/L)2.6 ± 0.72.8 ± 0.82.5 ± 0.6NS2.7 ± 0.62.8 ± 1.0NS
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 16 (9)
Journal of the American Society of Nephrology
Vol. 16, Issue 9
1 Sep 2005
  • Table of Contents
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Left Ventricular Morphology and Function in Patients with Atherosclerotic Renovascular Disease
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Left Ventricular Morphology and Function in Patients with Atherosclerotic Renovascular Disease
Julian R. Wright, Ala’a E. Shurrab, Anne Cooper, Paul R. Kalra, Robert N. Foley, Philip A. Kalra
JASN Sep 2005, 16 (9) 2746-2753; DOI: 10.1681/ASN.2005010043

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Left Ventricular Morphology and Function in Patients with Atherosclerotic Renovascular Disease
Julian R. Wright, Ala’a E. Shurrab, Anne Cooper, Paul R. Kalra, Robert N. Foley, Philip A. Kalra
JASN Sep 2005, 16 (9) 2746-2753; DOI: 10.1681/ASN.2005010043
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy
  • Lower Progression Rate of End-Stage Renal Disease in Patients with Peripheral Arterial Disease Using Statins or Angiotensin-Converting Enzyme Inhibitors
  • IgACE: A Placebo-Controlled, Randomized Trial of Angiotensin-Converting Enzyme Inhibitors in Children and Young People with IgA Nephropathy and Moderate Proteinuria
Show more Clinical Nephrology

Cited By...

  • Predictors of cardiac benefits of renal artery stenting from a multicentre retrospective registry
  • Optimising care at the cardio-renal interface
  • Incidental Renal Artery Stenosis Is an Independent Predictor of Mortality in Patients with Peripheral Vascular Disease
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire